What is the current Price Target for the Mineralys Therapeutics stock?

The average Mineralys Therapeutics target price is $31.67. This is 217.94% higher than the current stock price. The highest price target is 351.81%, the lowest is 140.96%. 6 Analysts have issued a price target Mineralys Therapeutics 2026 .

How high will the Mineralys Therapeutics stock rise?

No reliable answer can be given as to how high the Mineralys Therapeutics stock will rise. The performance of stocks, including the Mineralys Therapeutics stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Mineralys Therapeutics stock today?

The performance of Mineralys Therapeutics stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Mineralys Therapeutics stock fall?

The decline in Mineralys Therapeutics stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Mineralys Therapeutics Forecast, price target & analysts

$9.42

5.47% today

NYSE, Feb 28, 08:49 pm CET

ISIN

US6031701013

Symbol

MLYS

Reports

Quarter | Annual

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Mineralys Therapeutics Target price 2025 - Analyst rating & recommendation

Mineralys Therapeutics Classifications & Recommendation:

Buy

100%

Mineralys Therapeutics Price Target

Target Price	$31.67
Price	$9.96
Potential	217.94% register free of charge
Number of Estimates	6

	6 Analysts have issued a price target Mineralys Therapeutics 2026 . The average Mineralys Therapeutics target price is $31.67. This is 217.94% register free of charge higher than the current stock price. The highest price target is $45.00 351.81% register free of charge , the lowest is $24.00 140.96% register free of charge .
	A rating was issued by 7 analysts: 7 Analysts recommend Mineralys Therapeutics to buy, 0 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Mineralys Therapeutics stock has an average upside potential 2026 of 217.94% register free of charge . Most analysts recommend the Mineralys Therapeutics stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Dec '24	2025 Estimates
Earnings Per Share $	-3.66	-3.91
	83.92%	6.83%
P/E		negative

2 Analysts have issued a Mineralys Therapeutics forecast for earnings per share. The average Mineralys Therapeutics <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2024. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2024	$-3.66	83.92%
2025	$-3.91 6.83% Unlock
2026	$-4.02 2.81% Unlock
2027	$-4.08 1.49% Unlock
2028	$-2.24 45.10% Unlock
2029	$1.32 158.93% Unlock

Current	-2.73	76.24%
2025	-2.55 6.59% Unlock
2026	-2.48 2.75% Unlock
2027	-2.44 1.61% Unlock
2028	-4.45 82.38% Unlock
2029	7.57 270.11% Unlock

Mineralys Therapeutics...

Current Mineralys Therapeutics Upgrades & Downgrades Beta

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
Guggenheim	Locked ➜ Locked	Locked	Feb 24 2025
Goldman Sachs	Locked ➜ Locked	Locked	Feb 13 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Feb 13 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Nov 12 2024
HC Wainwright & Co.	Locked ➜ Locked	Locked	Oct 31 2024

Analyst Rating	Date
Locked Guggenheim: Locked ➜ Locked	Feb 24 2025
Locked Goldman Sachs: Locked ➜ Locked	Feb 13 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Feb 13 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Nov 12 2024
Locked HC Wainwright & Co.: Locked ➜ Locked	Oct 31 2024

Discover more stocks with a high price target

Coinbase Global, Inc. 60.51%

BioNTech SE - ADR 30.07%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now